Technology
Health
Biotechnology

Ophthotech

$1.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (1.31%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Ophthotech and other stocks, options, ETFs, and crypto commission-free!

About

Ophthotech Corporation Common Stock, also called Ophthotech, is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. Read More The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Employees
35
Headquarters
New York, New York
Founded
2007
Market Cap
63.34M
Price-Earnings Ratio
1.04
Dividend Yield
0.00
Average Volume
317.14K
High Today
$1.56
Low Today
$1.45
Open Price
$1.53
Volume
86.38K
52 Week High
$4.50
52 Week Low
$1.02

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2013 IPO
US

News

Associated PressMar 6

Ophthotech to Present at the Cowen and Company 39th Annual Health Care Conference

This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. NEW YORK--(BUSINESS WIRE)--Mar 6, 2019--Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer of Ophthotech, will present an overview of the Company at the Cowen and Company 39...

19
Simply Wall StFeb 27

Some Ophthotech Shareholders Have Copped A 97% Share Price Wipe Out

Ophthotech Corporation (NASDAQ:OPHT) shareholders should be happy to see the share price up 14% in the last month. But only the myopic could ignore the astounding decline over three years. Indeed, the share price is down a whopping 97% in the last three years. So it’s about time shareholders saw some gains. Only time will tell if the company can sustain the turnaround. While a drop like that is definitely a body blow, money isn’t as important as health and happiness. Check out our latest analysis for Opht...

118
Yahoo FinanceFeb 27

Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus

Improvement in restructured businesses and better-than-expected execution of coating services business help Aegion (AEGN) to post higher Q4 earnings.

20

Earnings

-$0.62
$1.34
$3.29
$5.25
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.